Wall Street Isn't Giving Up on CVS Health -- and Its Valuation Looks Stronger Than Investors Think

CVS reported 2Q revenue of $106.1B (+7.3% YoY) and EPS of $2.31 (+188% YoY), alongside an upgrade to 2026 guidance: revenue to at least $414B (from $405B) and EPS to $6.84–$7.04 (from $6.24–$6.44). Despite the beat and raised outlook, investors remain concerned about margin pressure in the PBM business, including Caremark membership declines in 2027 and ongoing 340B pricing headwinds tied to manufacturer restrictions. The PBM segment faces heightened FTC scrutiny and proposed PBM pricing transparency legislation, while CVS shares are still down >12% over the past month.

Analysis

The near-term earnings pop matters less than the quality of the earnings engine. CVS can still print strong EPS while the market quietly re-prices the franchise around lower PBM economics and more regulated reimbursement. That creates a classic trap: headline growth can coexist with a lower terminal multiple if the cash-flow contributor with the best operating leverage is entering a slower-growth phase.

The second-order effect is competitive, not just company-specific. If PBM pricing transparency and manufacturer pushback keep tightening, scale becomes a mixed blessing: large incumbents can absorb some hit through cross-segment offsets, but they also become the easiest target for regulators. UNH is the cleaner large-cap comparator because its mix is less tethered to the same near-term political narrative, while smaller PBMs may see incremental RFP wins if employers want simpler contracts and less headline risk.

The consensus seems too focused on the valuation gap versus near-term guidance and too relaxed about timing. A 2027 membership decline is not a distant problem in equity terms; stocks typically start discounting that inflection 12-18 months early. The contrarian view is that the stock may be optically cheap but not actually mispriced if the market is correctly anticipating slower multiple expansion once the PBM segment stops being the growth cushion.

Catalysts are mostly slower-burn: 1-3 months for FTC/legislative headlines and any further commentary on 340B pressure; 6-18 months for proof that Aetna medical cost trends remain contained without relying on unusually favorable utilization. What would falsify the bearish view is sustained margin stability in Caremark plus clean retention commentary into year-end, not a single quarter of earnings beat.

Key Decisions for Investors

• Do not chase CVS after the guide-up; wait for a pullback or for the stock to prove it can hold current levels after the next round of PBM/regulatory headlines. Use the low-$60s as a practical alert zone; if shares fail there, the risk/reward on new longs worsens quickly.
• Relative-value idea: short CVS against long UNH on any strength if the market starts rewarding the cleaner regulatory profile and punishing PBM scrutiny. Horizon: 3-6 months. Falsifier: CVS demonstrates stable Caremark retention and no incremental 340B deterioration, while UNH faces its own margin reset.
• For dividend-oriented exposure, prefer a covered-call or collar structure on CVS rather than an outright naked long. The dividend looks protected, but the multiple is likely range-bound until there is clearer evidence that PBM margin pressure is contained.
• Set a watch item on 2027 Caremark membership commentary and any quantitative disclosure around 340B headwinds. If management signals low-single-digit or worse membership attrition, reduce exposure ahead of the market's de-rating phase.
• No outright short is attractive here unless the stock re-rates materially higher first; the payout support and valuation floor make downside more gradual than in a typical deteriorating story.